INSM
Insmed Incorporated
NMS
$103.73
-2.30
(-2.17%)
Pullback · -1.71σ
Grade C
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$22.5B
P/E ttm
—
Fwd P/E
256.7
Beta
0.89
Day range
$103.73
52w range
$98.90 – $208.81
Avg vol
2.9M
RSI(2)
9.4
ROE
-294.5%
Net mgn
-144.4%
FCF mgn
-74.0%
Debt/Eq
1.05
Div yld
—
Sector
Healthcare
Industry
Biotechnology
Next earn
2026-08-06
Matrix setup grades
Long
C
score 28 · tech 28 / 80 · support 0 / 20
KC2 lower, -1.55 ATR from EMA21 · doji
- · KC2 lower stretch — standard mean-reversion tier
- · Doji — indecision, watch for reversal
- · Counter-trend long in breakout_down
Short
—
score 22 · tech 22 / 80 · support 0 / 20
below KC1 upper, -1.55 ATR from EMA21 · doji
- · Doji — indecision, watch for reversal
- · Aligned with breakout_down (strong tailwind)
Options · swing
See more →
CALL
$120
2026-07-17
$3.11
PUT
$90
2026-07-17
$2.15
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- -0.76 / -1.00
- Surprise
- +23.9%
- Next report
- 2026-08-06
About
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a…